Statement

  • Statement

    Incubate Comment in Response to the FTC’s Request for Comments on the Business Practices of PBMs
    05.25.2022

    Read Incubate's response to the FTC's Solicitation for Public Comments on the Business Practices of Pharmacy Benefit Managers and Their Impact on Independent Pharmacies and Consumers 

  • Statement

    Incubate Executive Director John Stanford Statement in Response to the Centers for Medicare & Medicaid Services’ Devastating Final National Coverage Determination for Certain Alzheimer’s Treatments
    04.14.2022

    See Executive Director John Stanford's statement on CMS' Final NCD on Alzheimer's disease and how this will affect the future of biopharmaceutical investment.

  • Statement

    Incubate Letter in Opposition to MA S. 2774
    04.07.2022

    See Incubate's letter to the Massachusetts state legislature in opposition to S. 2774

  • Statement

    Incubate Letter in Opposition to CT SB-13
    03.29.2022

    See Incubate's letter to Connecticut legislature opposing SB-13.

  • Statement

    Gaurav Gupta Comment on the Proposed Decision for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease
    02.10.2022

    Incubate Advisory Council member Gaurav Gupta's comment on CMS's Proposed Decision for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease

  • Statement

    Incubate Comment on the Proposed Decision Memo for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease
    02.10.2022

    Executive Director John Stanford's comment on CMS's Proposed Decision for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease

  • Statement

    Moonshot Statement
    02.02.2022

    Read Incubate Executive Director John Stanford's statement on President BIden's Moonshot initiative.

  • Statement

    Leading Venture Capital Group Alarmed By Build Back Better Act’s Prescription Drug Provision
    11.19.2021

    John Stanford, Executive Director of Incubate, a coalition of America's early-stage life sciences investors, issued the following statement on congressional Democrats' passage of the Build Back Better Act

  • Statement

    Leading Venture Capital Group Concerned with Prescription Drug Deal
    11.04.2021

    "As investors in biotechnology and pharmaceuticals, we're highly concerned about the potential consequences of the new drug-pricing legislation before Congress in the Build Back Better Act."

  • Statement

    Statement in response to the release of the Reduced Costs and Continued Cures Act
    09.15.2021

  • Statement

    Letter to President Biden, Secretary Becerra, Speaker Pelosi, Minority Leader McCarthy, Senate Majority Leader Schumer, and Senate Minority Leader McConnell opposing HR 3
    09.08.2021

    Members of the VC community voice concerns over HR 3 to policymakers

  • Statement

    Incubate Statement on Introduction of the PASTEUR Act
    06.22.2021

    Incubate commends Senators Michael Bennet (D-CO) and Todd Young (R-IN) and Representatives Mike Doyle (D-PA) and Drew Ferguson (R-GA) for re-introducing the Pioneering Antimicrobial Subscriptions to End Up surging Resistance (PASTEUR) Act.